A 62-year-old man from Delhi presents with a 3-year history of progressive tremor at rest, rigidity, and bradykinesia. He was started on levodopa-carbidopa 6 months ago and initially responded well. However, over the past 2 months, he has developed involuntary choreiform movements of the limbs and trunk that worsen with peak drug levels. His wife reports he now experiences sudden "on-off" fluctuations in motor control throughout the day. Which of the following best explains the development of these involuntary movements?

Explanation

## Mechanism of Levodopa-Induced Dyskinesias (LID) ### Pathophysiology The development of involuntary choreiform movements (dyskinesias) and motor fluctuations in this patient represents **levodopa-induced dyskinesias (LID)**, a hallmark complication of long-term dopamine replacement therapy in Parkinson's disease. ### Why Pulsatile Dopamine Stimulation Causes LID **Key Point:** In healthy brains, dopamine neurons provide continuous, physiological dopamine levels to the striatum. In advanced PD, the remaining dopaminergic neurons are unable to buffer and regulate exogenous levodopa, resulting in pulsatile (on-off) dopamine receptor stimulation. 1. **Progressive neuronal loss** in PD reduces the capacity of surviving neurons to store and release dopamine smoothly 2. **Oral levodopa dosing** creates peaks and troughs in blood and brain dopamine levels 3. **Pulsatile receptor activation** (rather than continuous) triggers maladaptive changes in striatal neurons: - Altered gene expression (FosB, ΔFosB accumulation) - Changes in glutamate and GABA signaling - Sensitization of D1-receptor-bearing medium spiny neurons 4. Result: **dyskinesias emerge at peak drug levels** (peak-dose dyskinesias) ### Clinical Correlate The temporal relationship between dyskinesias and drug levels is diagnostic: - **Peak-dose dyskinesias** → occur when levodopa levels are highest - **Diphasic dyskinesias** → occur at rising and falling drug levels - **Off-period dyskinesias** → occur when drug levels are low This patient's choreiform movements worsening at peak drug levels fit the **peak-dose dyskinesia** pattern, confirming pulsatile dopamine replacement as the mechanism. ### Management Implications | Strategy | Mechanism | Efficacy | |----------|-----------|----------| | Increase dosing frequency (smaller, more frequent doses) | Smooths dopamine levels | Moderate | | Add dopamine agonists | Provides continuous receptor stimulation | Moderate to high | | Add COMT inhibitors (entacapone) | Prolongs levodopa half-life | Moderate | | Deep brain stimulation (DBS) | Bypasses dopamine system | High | | Levodopa patch (experimental) | Continuous transdermal delivery | Under investigation | **High-Yield:** The key insight is that LID is NOT due to levodopa toxicity, but rather due to the **loss of buffering capacity** in the dopaminergic system combined with **pulsatile replacement**, which the denervated striatum cannot tolerate. [cite:Harrison 21e Ch 427]